Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
July 24, 2019 - Samsung Bioepis announced the FDA approval of Hadlima (adalimumab-bwwd), a biosimilar to AbbVie’s Humira® (adalimumab).
Download PDF
Return to publications
